|Bid||2.24 x 3000|
|Ask||2.28 x 1100|
|Day's Range||2.20 - 2.28|
|52 Week Range||2.03 - 12.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.75|
This week was a rough one for biotech company Pain Therapeutics, Inc. (NASDAQ:PTIE) after the firm’s pain drug, Remoxy ER, was shot down by the FDA advisory committee. PTIE stock had been trading at more than $9 per share ahead of the news and investors were hopeful about the drug’s potential. The biotech space is a risky one because FDA approval weighs so heavily on companies’ success.
Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...
CUPERTINO, Calif. , June 26, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety ...
AUSTIN, Texas, June 26, 2018-- Pain Therapeutics, Inc., a drug development company, today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety ...
Biotech stocks saw some upward momentum last week. The defensive nature of biotech stocks drove investors into the space amid a rise in risk aversion following the ongoing U.S.-China trade war. The week ...
The month of May saw several drugs passing the FDA muster, with new molecular entity approvals alone totaling five. NMEs are those innovative new products containing active moieties that haven't been approved ...
NEW YORK, May 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cision ...
–June 26 th Advisory Committee Meeting for REMOXY ER–. –August 7 th PDUFA Target Date for REMOXY ER–. AUSTIN, Texas, May 09, 2018-- Pain Therapeutics, Inc., a drug development company, today reported financial ...
Full Time Employees: 9
Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas.